Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sofinnova Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
2,015,644Website Global Rank
8,743Website Monthly Traffic
Twitter Followers
Description
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2016 | Corwave | Series B | 17.1M |
| 7/2007 | Diatos | Series D | 12.8M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 12/2007 | PregLem | Series B | 32.2M |
| 5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
| 4/2022 | Prometheus Materials | Series A | 8M |
| 8/2021 | TISSIUM | Series C | 59.1M |
| 4/2020 | EnginZyme | Series A | 6.9M |
| 7/2019 | Abivax | Post-IPO Equity | 13.5M |
| 3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
| 4/2013 | MedDay | Series A | 10.5M |
| 10/2002 | Cobion | Venture Round | 5.9M |
| 1/2016 | ENYO Pharma | Series A | 23.9M |
| 8/2006 | Ablynx | Series C | 50M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 8/2000 | BioSpace | Series B | 10M |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
| 3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
| 9/2010 | Bee Ware | Series B | 5.6M |
| 5/2005 | Bee Ware | Series A | 3.8M |
| 3/2008 | Filao | Venture Round | 0 |
| 12/2007 | Ascendis Pharma | Series A | 25.7M |
| 3/2005 | Filao | Venture Round | 4.6M |
| 3/2016 | CelluComp | Venture Round | 5.3M |
| 4/2014 | ProQR Therapeutics | Series A | 57.9M |
| 7/2020 | Enthera | Series A | 0 |
| 1/2007 | Stentys | Seed Round | - |
| 3/2018 | SafeHeal | Series A | 7.4M |
| 11/2021 | Synthace | Series C | 35M |
| 1/2006 | Blyk | Series A | 35.4M |
| 10/2022 | Mablink Bioscience | Series A | 30.1M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 1/2010 | BioAmber | Series A | 0 |
| 7/2021 | protera | Series A | 0 |
| 9/2013 | Synthace | Seed Round | 2.1M |
| 5/2004 | Addex Therapeutics | Series B | 0 |
| 3/2009 | Neosens | Series B | 5.3M |
| 2/2008 | Neosens | Venture Round | 3.7M |
| 5/2009 | MXP4 | Series B | 2.7M |
| 3/2007 | MXP4 | Series A | 6.5M |
| 1/2004 | Infra Worlds | Series A | 1.7M |
| 5/2023 | BrightHeart | Seed Round | 2.1M |
| 11/2013 | Pixium Vision | Series A | 20.3M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
| 4/2020 | RefleXion Medical | Series D | 0 |
| 3/2018 | Micropep Technologies | Series A | 5M |
| 1/2008 | CrestaTech | Series A | 5M |
| 1/2005 | CrestaTech | Seed Round | 1.5M |
| 1/2009 | DBV Technologies | Series B | 7.8M |
| 1/2006 | DBV Technologies | Venture Round | 15.1M |
| 1/2013 | ProQR Therapeutics | Seed Round | - |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 2/2003 | Avaki | Series A | 4.2M |
| 4/2006 | Endoart | Series C | 0 |
| 3/2008 | Laszlo Systems | Series C | 14.6M |
| 7/2019 | AblaCare | Series A | 11.2M |
| 4/2016 | MedDay | Series B | 0 |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
| 12/2021 | DMC Biotechnologies | Series B | 0 |
| 12/2019 | DMC Biotechnologies | Series A | 0 |
| 11/2011 | NuCana BioMed | Series A | 10.5M |
| 12/2022 | EnginZyme | Series B | 22.3M |
| 5/2022 | GFBiochemicals | Series A | 0 |
| 2/2017 | Zyl | Venture Round | - |
| 12/2018 | Shockwave Medical | Series D | 0 |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 3/2000 | Innate Pharma | Series A | 4.4M |
| 3/2017 | Biotalys | Series B | 0 |
| 1/2002 | Innate Pharma | Series B | 17.8M |
| 4/2004 | Ablynx | Series B | 30M |
| 7/2007 | Inside Secure | Series B | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 12/2013 | Green Biologics | Series B | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
| 7/2006 | Accent | Venture Round | 13.3M |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 5/2019 | DNA Script | Series B | 38.5M |
| 10/2006 | Domain Therapeutics | Series C | 10.4M |
| 1/2009 | Revolt Technology | Series B | 13.1M |
| 11/2003 | Esmertec AG | Series C | 0 |
| 6/2005 | Revolt Technology | Series A | 8.5M |
| 5/2015 | Twenga | Series A | 11M |
| 6/2021 | Borea Therapeutics | Seed Round | - |
| 10/1998 | BoostWorks | Series A | 3M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 1/2004 | Intransa | Series C | 8M |
| 4/2008 | Qosmos | Series C | 10.8M |
| 11/2021 | GlycoEra | Series A | 0 |
| 2/2002 | Tak Imaging | Series B | 9.5M |
| 5/2010 | Crocus Technology | Series C | 0 |
| 10/2004 | Sensitive Object | Series A | 2.5M |
| 1/2005 | VoluBill | Series C | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 9/2019 | Inotrem | Series B | 43.1M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 4/2018 | LimFlow SA | Series C | 33.4M |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 7/2005 | Filao | Venture Round | 0 |
| 7/2007 | GlycoVaxyn | Series A | 9.5M |
| 9/2007 | Purple Labs | Series A | 12.7M |
| 4/2002 | Esmertec AG | Venture Round | 8.8M |
| 4/2013 | Aledia | Series A | 12.8M |
| 11/2002 | PhyFlex Networks | Series B | 0 |
| 7/2021 | protera | Series A | 0 |
| 1/2019 | HighLife | Series B | 36M |
| 7/2019 | Biotalys | Series C | 0 |
| 7/2021 | Micropep Technologies | Series A | 10.1M |
| 6/2022 | Micropep Technologies | Series A | 0 |
| 2/2002 | Domain Therapeutics | Series A | 2.6M |
| 1/2007 | Movetis | Series A | 63.8M |
| 10/2010 | ASSIA | Series D | 20.8M |
| 7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
| 6/2010 | QuesCom | Venture Round | 0 |
| 1/2003 | Intransa | Series B | 6M |
| 7/2002 | Addex Therapeutics | Series A | 9.9M |
| 4/2020 | Pi-Cardia | Venture Round | 27M |
| 9/2017 | Synthace | Series A | 9.9M |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 3/2004 | UPEK | Series A | 20M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 4/2005 | Tak Imaging | Series C | 10M |
| 9/2002 | Ablynx | Series A | 4.9M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
| 1/2004 | Tak Imaging | Series C | 16.3M |
| 7/1999 | BoostWorks | Series B | 7M |
| 6/2020 | Protera | Series A | 5.6M |
| 2/2013 | MetGen | Venture Round | 2.9M |
| 3/2008 | Mobile Digital Media | Venture Round | 0 |
| 7/2019 | Comet Biorefining | Venture Round | - |
| 1/2015 | Green Biologics | Equity | 42M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 12/2007 | Streamezzo | Series C | 22M |
| 8/2004 | Intransa | Series D | 24M |
| 1/2005 | Biolipox | Series C | 41M |
| 2/2002 | Intransa | Venture Round | 10M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 2/2015 | Synthace | Venture Round | 3.4M |
| 11/2006 | CoreValve | Venture Round | 20M |
| 5/2004 | Domain Therapeutics | Series B | 19.1M |
| 5/2010 | Noxxon Pharma | Series D | 40.7M |
| 10/2009 | Crescendo Biologics | Seed Round | 0 |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 1/2018 | Aledia | Series C | 0 |
| 5/2007 | Noxxon Pharma | Series C | 50.2M |
| 7/2006 | GlycoVaxyn | Seed Round | - |
| 3/2014 | Inotrem | Series A | 25.1M |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 9/2020 | POLYNEURON | Series A | 15.4M |
| 4/2018 | Erydel | Series B | 32.4M |
| 5/2014 | Avantium | Series G | 0 |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 4/2014 | RefleXion Medical | Series A | 11.6M |
| 11/2014 | myTomorrows | Venture Round | 5.6M |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 2/2012 | BioAmber | Series C | 0 |
| 10/2017 | HighLife | Series A | 14.3M |
| 7/2018 | HotSpot Therapeutics | Series A | 45M |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 10/2011 | Creabilis | Series B | 20M |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 6/2015 | Aledia | Series B | 0 |
| 11/2019 | TISSIUM | Series B | 43.2M |
| 4/2006 | Varioptic | Series C | 0 |
| 7/2019 | Microphyt | Venture Round | 31.9M |
| 6/2018 | Castle Biosciences | Venture Round | 0 |
| 4/2015 | ReCor Medical | Series D | 15M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 6/2009 | blueKiwi software | Series B | 0 |
| 1/2008 | TAK imaging | Series C | 16.2M |
| 9/2002 | EnvoyWorldWide | Series C | 4.5M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 2/2019 | AFYREN | Venture Round | 23.8M |
| 12/2021 | EndoRon Medical | Seed Round | 5M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 1/2003 | Biolipox | Series B | 21M |
| 3/2008 | Stentys | Series A | 18M |
| 1/2007 | blueKiwi software | Series A | 5.3M |
| 2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 2/2021 | Mainstay Medical | Private Equity Round | 0 |
| 6/2018 | NodThera | Series A | 40M |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 10/2003 | Cotherix | Series C | 55M |
| 4/2014 | NuCana | Series B | 0 |
| 3/2004 | Varioptic | Series B | 12.2M |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 4/2016 | RefleXion Medical | Series B | 52M |
| 9/2004 | Innate Pharma | Series C | 0 |
| 5/2009 | Streamezzo | Series D | 5.5M |
| 4/2018 | RefleXion Medical | Series C | 100M |
| 2/2016 | Corvidia | Series A | 26M |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
| 4/2006 | Streamezzo | Series B | 0 |
| 4/2018 | EnobraQ | Seed Round | 3.6M |
| 7/2021 | Comet Biorefining | Series C | 0 |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2016 | MD Start | Venture Round | 0 |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 3/2017 | Comet Biorefining | Venture Round | - |
| 6/2021 | Alia Therapeutics | Seed Round | - |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2013 | MetGen | Series A | - |
| 3/2007 | CoreValve | Series C | 33M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 12/2020 | Noema Pharma | Series A | 60M |
| 6/2020 | NodThera | Series B | 55M |
| 9/2007 | VoluBill | Series D | 0 |
| 1/2017 | myTomorrows | Venture Round | 10.6M |
| 3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 1/2008 | Inside Secure | Series C | 0 |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 4/2005 | Laszlo Systems | Series B | 6.3M |
| 3/2017 | Breath Therapeutics | Series A | 45.9M |
| 4/2018 | Corvidia | Series B | 60M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 11/2013 | CelluComp | Seed Round | 3.9M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 4/2020 | Pyrowave | Series B | - |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 2/2010 | Odoo | Series A | 4.1M |
| 1/2021 | Corwave | Series C | 43.2M |
| 7/2018 | Enthera | Seed Round | 4.7M |
| 4/2013 | Auris Medical | Series C | 51M |
| 9/2006 | Qosmos | Series B | 4.1M |
| 6/2021 | AAVantgarde Bio | Seed Round | - |
| 1/2014 | Shockwave Medical | Series A | 12.5M |
| 2/2022 | Elicit Plant | Series A | 18.3M |
| 3/2019 | POLYNEURON | Series A | 22.6M |
| 11/2020 | Myricx Pharma | Seed Round | 5.9M |
| 6/2022 | Moon Surgical | Series A | 31.3M |
| 2/2015 | Comet Biorefining | Venture Round | - |
| 1/2002 | EnvoyWorldWide | Series B | 8M |
| 3/2017 | HotSpot Therapeutics | Seed Round | - |
| 1/2003 | Varioptic | Series A | 2.1M |
| 2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
| 12/2009 | Sensitive Object | Series B | 6M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
| 11/2015 | ObsEva | Series B | 58.9M |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 6/2005 | Endotis | Series A | 4.9M |
| 4/2020 | Genespire | Series A | 17.4M |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 11/2022 | Microphyt | Series B | 0 |
| 11/2011 | NuCana | Series A | 0 |
| 4/2005 | TAK imaging | Series C | 10M |
| 6/2008 | Creabilis | Series A | 31.4M |
| 9/2006 | Oxxius | Series B | 10M |
| 5/2014 | Odoo | Series B | 10M |
| 10/2006 | Wyplay | Series A | 5.1M |
| 9/2004 | Oxxius | Series A | 2.9M |
| 5/2005 | Sefas Innovation | Venture Round | 3.8M |
| 9/2016 | Delinia | Series A | 35M |
| 1/2022 | SafeHeal | Venture Round | 0 |
| 3/2016 | TISSIUM | Series A | 25.5M |
| 6/2007 | PregLem | Series A | 26M |
| 8/2008 | mydeco | Series A | 14.5M |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 7/2010 | Mainstay Medical | Series A | 6.1M |
| 4/2020 | Epsilen Bio | Seed Round | - |
| 5/2023 | BrightHeart | Seed Round | 0 |
| 5/2023 | TISSIUM | Series D | 0 |
| 5/2023 | Moon Surgical | Series B | 0 |
| 5/2023 | Werewool | Seed Round | 0 |
| 4/2023 | Alia Therapeutics | Seed Round | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 3/2023 | deepc | Series A | 0 |
| 3/2023 | Kiro | Series A | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
